{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.8","upperLimit":"69.4","value":"47.8"},{"groupId":"OG001","lowerLimit":"34.8","upperLimit":"93.3","value":"70.0"},{"groupId":"OG002","lowerLimit":"16.3","upperLimit":"67.7","value":"40.0"},{"groupId":"OG003","lowerLimit":"52.2","upperLimit":"78.2","value":"66.1"},{"groupId":"OG004","lowerLimit":"42.4","upperLimit":"69.3","value":"56.1"},{"groupId":"OG005","lowerLimit":"39.3","upperLimit":"68.2","value":"54.0"},{"groupId":"OG006","lowerLimit":"32.9","upperLimit":"61.5","value":"47.1"},{"groupId":"OG007","lowerLimit":"39.3","upperLimit":"65.4","value":"52.5"},{"groupId":"OG008","lowerLimit":"49.3","upperLimit":"73.8","value":"62.1"},{"groupId":"OG009","lowerLimit":"39.3","upperLimit":"68.2","value":"54.0"},{"groupId":"OG010","lowerLimit":"28.8","upperLimit":"57.8","value":"42.9"},{"groupId":"OG011","lowerLimit":"34.4","upperLimit":"63.7","value":"49.0"},{"groupId":"OG012","lowerLimit":"30.7","upperLimit":"59.8","value":"44.9"},{"groupId":"OG013","lowerLimit":"60.8","upperLimit":"89.9","value":"77.8"},{"groupId":"OG014","lowerLimit":"63.1","upperLimit":"91.6","value":"80.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"56"},{"groupId":"OG004","value":"57"},{"groupId":"OG005","value":"50"},{"groupId":"OG006","value":"51"},{"groupId":"OG007","value":"61"},{"groupId":"OG008","value":"66"},{"groupId":"OG009","value":"50"},{"groupId":"OG010","value":"49"},{"groupId":"OG011","value":"49"},{"groupId":"OG012","value":"49"},{"groupId":"OG013","value":"36"},{"groupId":"OG014","value":"35"}],"units":"Participants"}],"description":"The percentage of participants whose best overall response (BOR) is CR, PR or SD in the population of interest. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Failure to meet criteria for complete or partial response, in the absence of progressive disease. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1/0.3/1/3/10 mg/kg every 2 weeks","id":"OG000","title":"Cohort 1 Uninfected HCC"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3/1/3 mg/kg every 2 weeks","id":"OG001","title":"Cohort 1 HCV Infected"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1/0.3/1/3 mg/kg every 2 weeks","id":"OG002","title":"Cohort 1 HBV Infected"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib naive/intolerant received nivolumab 3 mg/kg every 2 weeks","id":"OG003","title":"Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib progressors received nivolumab 3 mg/kg every 2 weeks","id":"OG004","title":"Cohort 2 Uninfected Sorafenib Progressors: Treatment 2"},{"description":"Dose Expansion: Hepatitis C (HCV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG005","title":"Cohort 2 HCV Infected: Treatment 3"},{"description":"Dose Expansion: Hepatitis B (HBV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG006","title":"Cohort 2 HBV Infected: Treatment 4"},{"description":"Arm A: Advance hepatocellular carcinoma (HCC) participants received nivolumab 240 mg every 2 weeks","id":"OG007","title":"Cohort 3: Treatment 1"},{"description":"Arm B: Advance hepatocellular carcinoma (HCC) participants received Sorafenib 400 mg twice a day","id":"OG008","title":"Cohort 3: Treatment 2"},{"description":"Arm A: Participants received nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks","id":"OG009","title":"Cohort 4: Treatment 1"},{"description":"Arm B: Participants received nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks","id":"OG010","title":"Cohort 4: Treatment 2"},{"description":"Arm C: Participants received nivolumab 3 mg/kg every 2 weeks + ipilimumab 1 mg/kg every 6 weeks","id":"OG011","title":"Cohort 4: Treatment 3"},{"description":"Participants received nivolumab 240 mg every 2 weeks","id":"OG012","title":"Cohort 5: Treatment 1"},{"description":"Participants received nivolumab 240 mg every 2 weeks + cabozantinib 40 mg once daily","id":"OG013","title":"Cohort 6: Treatment 1"},{"description":"Participants received nivolumab 3 mg/kg every 2 weeks + ipilimumab 1 mg/kg every 6 weeks + cabozantinib 40 mg once daily","id":"OG014","title":"Cohort 6: Treatment 2"}],"paramType":"NUMBER","populationDescription":"All treated participants for Cohort 1, 2, and 5, and all randomized participants for Cohort 3, 4 and 6. Uninfected HCC, HCV-infected, and HBV-infected participants were pre-specified to be reported together for Cohort 1.","reportingStatus":"POSTED","timeFrame":"From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)","title":"Disease Control Rate (DCR) Assessed by Blinded Independent Central Review (BICR)","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}